2015
DOI: 10.1007/s00726-015-2027-9
|View full text |Cite
|
Sign up to set email alerts
|

The l-arginine/NO pathway, homoarginine, and nitrite-dependent renal carbonic anhydrase activity in young people with type 1 diabetes mellitus

Abstract: High circulating levels of asymmetric dimethylarginine (ADMA) and low circulating levels of homoarginine (hArg) are known cardiovascular risk factors in adults. While in adults with type 1 diabetes mellitus (T1DM) circulating ADMA is significantly elevated, in children and adolescents the reported ADMA data are contradictory. In 102 children with T1DM and 95 healthy controls (HC) serving as controls, we investigated the L-arginine (Arg)/nitric oxide (NO) pathway. Children with T1DM were divided into two groups… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
11
1

Year Published

2015
2015
2019
2019

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 22 publications
(15 citation statements)
references
References 59 publications
(78 reference statements)
3
11
1
Order By: Relevance
“…In addition, supplementation of homoarginine to control mice did not alter any hemodynamic parameters or body weight despite increasing plasma homoarginine levels (Atzler et al 2017;Karetnikova et al 2019). Although reduced L-homoarginine levels are a marker for cardiovascular and kidney disease (Morris et al 2011;Jud et al 2018;Martens-Lobenhoffer et al 2018), the role of L-homoarginine in diabetes remains controversial (Carmann et al 2015;Krebs et al 2015). In a diet-induced obese mouse model, Stockebrand et al (2015) reported that L-homoarginine supplementation reduced blood glucose and stimulated insulin production, despite having no effect on body weight or glucose tolerance.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, supplementation of homoarginine to control mice did not alter any hemodynamic parameters or body weight despite increasing plasma homoarginine levels (Atzler et al 2017;Karetnikova et al 2019). Although reduced L-homoarginine levels are a marker for cardiovascular and kidney disease (Morris et al 2011;Jud et al 2018;Martens-Lobenhoffer et al 2018), the role of L-homoarginine in diabetes remains controversial (Carmann et al 2015;Krebs et al 2015). In a diet-induced obese mouse model, Stockebrand et al (2015) reported that L-homoarginine supplementation reduced blood glucose and stimulated insulin production, despite having no effect on body weight or glucose tolerance.…”
Section: Discussionmentioning
confidence: 99%
“…The circulating concentration of ADMA in healthy children is more than two times higher than in healthy adults (Lücke et al 2007), suggesting that ADMA and presumably the whole Arg/NO pathway greatly differ between children/adolescents and adults, i.e., that children are not small adults. In the present work, emphasis was given to the Arg/NO pathway, including hArg in healthy children and adolescents, as well as in those suffering from type 1 diabetes mellitus, Duchenne muscular dystrophy, and growth hormone deficiency (GHD) (Carmann et al 2015;Hörster et al 2015;Langen et al 2015; see also Thum et al 2007).…”
Section: Introductionmentioning
confidence: 99%
“…These studies have led to the development of targeted therapy against CAs that are currently in clinical use for the treatment of diseases such as glaucoma, altitude sickness, and epileptic seizures. CA targeting inhibitors are now being tested in preclinical models for the treatment of diabetes and obesity, while others are currently in clinical trials as cancer therapies [ 4 11 ]. Combined, these studies show that CAs are important therapeutic targets for the treatment of an expanding array of human diseases.…”
Section: Introductionmentioning
confidence: 99%